LBRX LB PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, LB PHARMACEUTICALS INC reported revenue of n/a, net income of −$51.6M and diluted EPS of −$1.71; for the fiscal year ended December 2025 revenue was n/a.
LBRX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income n/a, net income −$25.2M (margin n/a), EPS −$3.13
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income n/a, net income −$63.1M (margin n/a), EPS −$176.15
LBRX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$51.6M, EPS −$1.71
- Quarter ended Mar 31, 2026: revenue n/a, net income −$19.1M, EPS −$0.67
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$11.5M, EPS $25.85
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.56M, EPS −$0.61
- Quarter ended Jun 30, 2025: revenue n/a, net income −$4.87M, EPS −$13.58
- Quarter ended Mar 31, 2025: revenue n/a, net income −$5.31M, EPS −$14.79
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$5.07M, EPS n/a
- Quarter ended Sep 30, 2024: revenue n/a, net income −$14.2M, EPS −$39.49
- Quarter ended Jun 30, 2024: revenue n/a, net income −$27.6M, EPS n/a
- Quarter ended Mar 31, 2024: revenue n/a, net income −$16.2M, EPS n/a
LBRX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$35.2M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$53.1M, share buybacks n/a
LBRX balance sheet
- Jun 30, 2026: cash $283M, total assets $362M, total liabilities $29.3M, shareholders' equity $332M
- Mar 31, 2026: cash $321M, total assets $393M, total liabilities $14.8M, shareholders' equity $379M
- Dec 31, 2025: cash $250M, total assets $313M, total liabilities $11.6M, shareholders' equity $301M
- Sep 30, 2025: cash $270M, total assets $321M, total liabilities $10.5M, shareholders' equity $310M
- Dec 31, 2024: cash $23.0M, total assets $33.5M, total liabilities $13.8M, shareholders' equity −$94.6M
Is LBRX profitable?
No. LB PHARMACEUTICALS INC lost $85.7M over the last four quarters.
What is LBRX's EPS?
Diluted earnings per share over the last four quarters were $22.86; −$1.71 in the latest quarter.